Medical Research

Early Results of First Trial Conducted Exclusively in People with Pre-Extensively Drug-Resistant Tuberculosis Show Promise

by

Paris/Boston, 13 November 2024 – The endTB consortium has completed endTB-Q, the first Phase 3 randomized controlled trial to exclusively enroll people suffering from pre-extensively drug-resistant tuberculosis (pre-XDR-TB), a very hard-to-treat form of tuberculosis (TB). The trial, conducted by the endTB consortium (Médecins Sans Frontières, Partners In Health, and IRD), demonstrated that a shorter treatment strategy … Read more

MSF Scientific Days – Asia 2024: Advancing Humanitarian Medical Innovation and Research Across Asia

by

25 October 2024, New Delhi: Medecins Sans Frontieres (MSF)/Doctors Without Borders Scientific Days – Asia 2024 held at the India Habitat Centre on 25th October 2024 brought together over 200 researchers, academics, and patient representatives dedicated to advancing humanitarian medical innovation and research. The conference held in collaboration with Atal Bihari Vajpayee Institute of Medical … Read more

Diabetes: MSF study shows some insulin can be stored at warmer temperatures

by

Good news for people with diabetes in places where refrigeration can be a luxury NEW YORK/GENEVA — A joint study published today in PLOS ONE by the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) and the University of Geneva shows that a range of insulins can be stored at warmer temperatures than previously recommended, making it easier … Read more

Overcoming neglect: Finding ways to manage and control NTDs

by

The report, Overcoming Neglect, details Doctors Without Borders/Médecins Sans Frontières’ (MSF) involvement with neglected tropical diseases (NTDs) over the last three decades. Our work includes treating patients, carrying out operational research, supporting efforts to identify new treatments and diagnostics; and playing an active role in reducing their incidence. We call for an improved global response to NTDs, … Read more